Introduction
The Hirata disease, also known as insulin autoimmune syndrome (IAS), is an unusual cause of hypoglycaemia characterized by high serum levels of insulin and a significant increase of endogenous antibodies which bind insulin/proinsulin and/or insulin receptor. [1] [2] [3] Described by Yukimasa Hirata in 1972, 4 IAS is the third commonest cause of spontaneous hypoglycaemia in Japan, after Insulinoma and extrapancreatic tumours. 5 IAS is closely related with HLA-DR4. In the Japanese population, HLA DRB1*04:06 and DRB1*04:03 (at lower level) are the alleles most frequently found in this clinical pattern. 6 Viral infections 7 and drugs composed of sulphur/sulfhydryl groups such as methimazole, 8 captopril, D-penicillamine, mercaptans, clopidogrel, imipenem, albumin and diltiazem have been considered as the potential factors inducing IAS. 9 In several cases, IAS has been described in patients affected by other autoimmune disorders, such as autoimmune thyroiditis, membrano-proliferative glomerulo-nephritis and rheumatoids arthritis. [10] [11] [12] [13] In 2003, at the Kyushu local meeting of the Japan Diabetes Society, Hashinaga T. et al. reported a clinical case of IAS due to an additional sulfhydryl drug defined α-lipoic acid (ALA). In the recent years, an increase in cases of ALAinduced IAS has been described. IAS related to ALA administration has been reported most frequently in Japanese and Koreans subjects. Recently, seven new cases have been described in Italian patients.
We report a case of IAS induced by ALA in an Argentine woman who referred to our Department.
Furthermore, we provide a literature review of all the cases of IAS due to ALA administration, in order to open a comprehensive overview of the characteristics of this unusual disease.
Case
A 66-year-old female referred to the Emergency Room for malaise and sweating. Laboratory findings showed low blood glucose level (2.56 mmol/L). She was admitted in our Department to study deeply the cause of hypoglycaemia. Informed consent was obtained.
Her clinical anamnesis was negative. Recently, due to joint pain, she started therapy with ALA (800 mg/day) for 1 month and, after a suspension of 15 days, she further continued for 10 days. Two weeks before the admission in our hospital, she discontinued this therapy due to repeated episodes of hand tremor and hunger that appeared 3-4 h after a meal. Furthermore, these symptoms regressed after sugar ingestion.
There was no family history of autoimmune or endocrine disorders.
The body weight was 72.55 kg and height was 170 cm (Body Mass Index 25.1 kg/m 2 ). At admission, heart rate was 84/min and blood pressure 120/80 mmHg. The patient was conscious and oriented. Clinical chest and heart exams were negative. She had no thyroid goitre, acanthosis, skin tags or clinical and serological evidence of underlying autoimmune disease. Neurological findings were normal.
Laboratory values showed normal results except for blood glucose levels: 3. Table 1 shows laboratory data on admission.
An oral glucose tolerance test performed over 240 min showed basal glucose value of 3.88 mmol/L, a peak of 6.9 mmol/L at 120 min and a nadir of 2.33 mmol/L at 240 min.
Therefore, we performed enzyme immunoassay to obtain a quantitative determination of IgG autoantibodies to insulin in human serum (MediZym, Autoantibodies to Insulin enzyme-linked immunosorbent assay (ELISA) Assay Kit, MEDIPAN). High titre of insulin antibodies (271 U/mL, n.v. < 0.4) had been detected.
We repeated blood sampling during a symptomatic episode of hypoglycaemia that confirmed the above-mentioned data: low blood glucose level (2.39 mmol/L), high levels of serum insulin (1971.55 pmol/L), inappropriately high levels of C-peptide (2.36 nmol/L) and high levels of insulin antibodies (274.78 IU/mL).
The 72-h fasting test was not performed due to the need for intravenous glucose support during the repeated and frequent hospital episodes of hypoglycaemia.
Abdominal computer tomography and Octreoscan scintigraphy excluded the presence of Insulinoma.
HLA-DNA typing identified DRB1*04:03. Patient required continuous iv 5% dextrose for 10 days. No further episodes of hypoglycaemia occurred. A diet with fractionated meals, composed of high-fibre foods and poor or fast-acting carbohydrate, was prescribed. Figure 1 shows blood glucose, insulin levels and antibodies levels during the hospitalization and follow-up.
Discussion
In most cases, IAS appears a few weeks after the administration of a drug containing sulfhydryl group.
The reducing activity of these compounds promotes the dissociation of the insulin S-S binding and exposes the insulin α chain to the antigen-presenting cells. 14 The amino acid sequence Ile-Leu-Gln, contained in the insulin α chain, has a strong affinity for DRB1*04:06 molecule. 14 Another peptide localized from no.8 to no.17 of the insulin α chain (TSICSLYQLE) shows a high affinity with this molecule. This amino acid sequence is able to stimulate the T cells of DRB1*04:06-positive patients, leading to the synthesis of polyclonal insulin autoantibodies. 14, 15 In 2003, Hashinaga T. et al. reported an IAS clinical case due to an additional sulfhydryl drug, namely ALA.
ALA, also called thioctic acid, is a compound with a strong reductive effect. 16 The antioxidant properties of α-lipoic acid play an essential role in the treatment of diabetic peripheral neuropathic pain. 17 It is well known that the overproduction of reactive oxygen species is a common factor in the pathogenesis of atherosclerosis, diabetes mellitus and hypertension.
Furthermore, ALA is widely used as a health supplement for dieting and antiaging. In the past 20 years, ALA is often used as a dietary supplement in Japan. In these years, several cases of IAS have been reported and, after methimazolo, ALA has been considered the main cause of this syndrome. 18 Table 2 shows a summary of ALA-induced IAS cases described from 2003 to May 2018. 13, [18] [19] [20] [21] [22] [23] The majority of cases reported in the table have been presented exclusively in scientific meetings. Overall, 27 cases of Hirata disease due to ALA administration has been documented: 18 in Japan, 7 in Italy and 2 in Korea. In 23 patients, HLA-DNA typing has been reported. A total of 13 of 17 Asiatic patients had the HLA-DRB1*04:06 allele compared with only 3 Asiatic patients with DRB1*04:03. All Caucasian patients were Italian, in six of those HLA-DRB1*04:03 was identified while HLA-DRB1*04:06 was isolated in two cases.
We describe the case of an Argentine woman presenting episodes of hypoglycaemia related to the ingestion of ALA. The association of hypoglycaemia with extremely high levels of serum insulin was indicative of IAS. Laboratory test showed inappropriately high level of C-peptide. It may be related to the cross-reactivity between C-peptide and proinsulin which may be immunologically counted and reported as 'free C-peptide'. 1, 24, 25 Although in the reported cases the syndrome occurs mainly with neuroglycopenic symptoms, our patient experienced adrenergic symptoms that occurred 2-3 h after a meal. As reported in the scientific literature, also in our patient the symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal. HLA-DNA typing identified DRB1*04:03. This finding confirms the implication of this allele in the genetic IAS predisposition also in not Asian population.
In our opinion, it is very suggestive that IAS related to ALA has been only described in the Asian population and in some Italian patients. The 'Allele Frequency Net Database' documented that HLADRB1*04:06 has a high prevalence in the Japanese population (allele frequency: 0.0339) while it is less common in Italy (allele frequency: 0.001). 26 HLADRB1*04:03 is common among Caucasians and the allele frequency in Italy and Argentine are, respectively, 0.01 and 0.014. Nevertheless, analysing the allele frequency distribution, in countries with a similar prevalence of HLADRB1*04:03 and common use of ALA (Germany, United States, etc.), no cases of Hirata disease related to ALA have been reported. This epidemiological data is very interesting, although we have not clear evidence to explain it. In our opinion, there are some promoting or protective factors (genetic? environmental?) which can induce or swich off this autoimmune reaction. This aspect needs to be deeply investigated.
In our patient, hypoglycemic symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal. After drug suspicion, the most effective therapy is usually the ingestion of several small amounts and avoiding meals with high glycaemic index carbohydrates. Otherwise, some patients required pharmacological intervention as alpha-glucosidase, corticosteroids, immunosuppressant and plasmapheresis. Alpha-glucosidase inhibitors, such as acarbose, delay the absorption of glucose, decreasing the hypersecretion of insulin. 27 Another possible therapy is corticosteroids. 8 Immunosuppressants and plasmapheresis may be used in not responsive patients. 18 
Conclusion
Nowadays, ALA therapy is widely used as a dietary and antiaging supplement or as adjuvant therapy for symptomatic diabetic peripheral neuropathy; it is useful to know that, in patients with a genetic predisposition, this treatment could induce IAS. A prompt diagnosis is required and a targeted diet should be applied; in some cases a pharmacological therapy in needed.
Declaration of conflicting interests
The author(s) declare no potential conflict of interest with respect to the research, authorship and publication of the article.
Ethics approval
Our institution does not require ethical approval for reporting individual cases.
Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.
Informed consent
Informed consent was obtained from the patient for anonymized patient information to be published in this article.
